LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・PTC Therapeutics Inc

PTC Therapeutics Inc

Closed

Sector Healthcare

31.52 0.19

Buy Sell

Overview

Share price change

24h

Current

Min

31.39

Max

31.69

Key metrics
By Trading Economics
Income	-7.6M -99M
Sales	-23M 187M
EPS	-1.29
Profit margin	-53.122
Employees	988
EBITDA	-47M -35M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+26.82 upside

Dividends
By Dow Jones
Next Earnings	24 Oct 2024

Market Stats
By TradingEconomics
Market Cap	101M 2.7B
Previous open	31.33
Previous close	31.52

News Sentiment

By Acuity

26%

74%

47 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

30.41 / 35.36 Support & Resistance

PTC Therapeutics Inc Chart

Related News

25 Jan 2024, 23:44 UTC

Hot Stocks

Stocks to Watch: Intel, PTC Therapeutics, KLA

28 Sept 2023, 23:57 UTC

Hot Stocks

Stocks to Watch: Nike, Novo Integrated, PTC Therapeutics

Peer Comparison

Price change

PTC Therapeutics Inc Forecast

Price Target

By TipRanks

26.82% upside

12 Months Forecast

Average 40 USD 26.82%

High 64 USD

Low 26 USD

Based on 15 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to PTC Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

30.41 / 35.36Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

47 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About PTC Therapeutics Inc

PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).